Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2024-08-30 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
2024年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳市海王生物工程股份有限公司2024 年半年度财务报告" which translates to "Shenzhen Haiwang Bioengineering Co., Ltd. 2024 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2024. The report explicitly states it is a half-year report and includes comprehensive financial data and analysis, not just an announcement or summary. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-30 Chinese
信息披露制度（2024年8月）
Governance Information Classification · 95% confidence The document is a detailed internal policy or system document titled "信息披露制度" (Information Disclosure System) for Shenzhen Haier Bioengineering Co., Ltd., revised in August 2024. It extensively covers the company's information disclosure rules, procedures, responsibilities, and compliance with Chinese securities laws and Shenzhen Stock Exchange regulations. It includes chapters on general principles, disclosure content and standards, reporting and approval processes, communication with investors and media, management responsibilities, confidentiality, and insider information. The document is not a financial report, earnings release, or announcement of a specific event but rather a governance and compliance manual related to information disclosure practices. It does not contain financial statements, audit opinions, voting results, or transaction details. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-08-30 Chinese
外部信息报送和使用管理制度（2024年8月）
Governance Information Classification · 95% confidence The document is titled '外部信息报送和使用管理制度' (External Information Reporting and Usage Management System) and details internal company policies and procedures regarding the management, confidentiality, and reporting of information to external parties. It references compliance with laws and regulations, confidentiality obligations, and internal controls related to information disclosure. There are no financial statements, earnings data, or report content. The document is a governance or internal control policy document rather than a financial report or announcement. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified under Governance Information (CGR) as it details the company's internal rules and governance practices regarding information disclosure and confidentiality.
2024-08-30 Chinese
募集资金管理制度（2024年8月修订草案）
Governance Information Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and is a detailed internal policy document outlining the management, use, supervision, and regulatory compliance related to the company's raised funds. It includes references to laws, regulatory requirements, and internal procedures for managing capital raised through securities issuance. The document is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and procedures for managing raised capital. It does not contain financial statements or earnings data, nor is it a brief announcement or presentation. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices related to capital management.
2024-08-30 Chinese
监事会关于第九届监事会第十四次会议相关事项的意见
Board/Management Information Classification · 95% confidence The document is a statement from the Supervisory Board (监事会) of Shenzhen Haiwang Bioengineering Co., Ltd. regarding their opinion on a specific meeting held on August 29, 2024. It discusses the approval of external guarantees related to subsidiaries and confirms that the matter does not harm the company or shareholders. The content is about board-level oversight and opinions on company matters, specifically related to guarantees and approvals. There is no indication of financial results, audit reports, voting results, or other report types. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management decisions and opinions.
2024-08-30 Chinese
关联交易管理制度（2024年8月）
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System' and contains detailed rules and principles governing related party transactions for Shenzhen Haier Bioengineering Co., Ltd. It references relevant laws, stock exchange listing rules, and internal governance practices. The content is a governance policy document outlining procedures, responsibilities, and compliance requirements for related party transactions rather than financial results, audit opinions, or meeting materials. It does not contain financial statements or earnings data, nor is it an announcement or a report publication notice. This type of document fits best under Governance Information (CGR), as it details internal rules and governance practices related to related party transactions.
2024-08-30 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.